2 ms·
If its track record of starting medical cost transparency is any indication, I'd say it's following a different path than what benefits big pharma.
by Fjolsvith 7y ago
If its track record of starting medical cost transparency is any indication, I'd say it's following a different path than what benefits big pharma.